Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: Disclosed herein are ?-glucosidase (GCase) chaperones and methods of using GCase chaperones in an individual in need thereof. GBA1 mutations lead to GCase deficiency and substrate accumulation, causing Gaucher disease. Currently, no FDA or EMA-approved therapeutic for neuronopathic Gaucher disease is available. Improved GCase activity in brain cells using a chaperone may reduce substrate accumulation and associated pathology. Disclosed herein are novel non-inhibitory chaperone compounds of GCase that have properties of a central nervous system drug. Those compounds effectively restored mutant GCase activity by stabilizing protein and enhancing lysosomal localization and may be useful for chaperone therapy to treat neuronopathic Gaucher disease and likely to Parkinson's disease.

Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: The present invention provides polypeptide modulators of complement activity, including cyclic polypeptide modulators. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: A process and a device are described for producing high purity and high temperature steam from non-pure water which may be used in a variety of industrial processes that involve high temperature heat applications. The process and device may be used with technologies that generate steam using a variety of heat sources, such as, for example industrial furnaces, petrochemical plants, and emissions from incinerators. Of particular interest is the application in a thermochemical hydrogen production cycle such as the Cu—Cl Cycle. Non-pure water is used as the feed-stock in the thermochemical hydrogen production cycle, with no need to adopt additional and conventional water pre-treatment and purification processes. The non-pure water may be selected from brackish water, saline water, seawater, used water, effluent treated water, tailings water, and other forms of water that is generally believed to be unusable as a direct feed-stock of industrial processes.

Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Abstract: The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.

Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Abstract: Dry powder inhalers and dry powder inhaler storage cassettes including a compartment housing an elongate carrier preloaded with a plurality of doses of finely divided powder comprising a biologically active substance, the compartment being configured such that said preloaded doses are sealed within said compartment and such that the carrier may be advanced from the compartment to the chamber through an exit provided with a moisture barrier sealing system, wherein the moisture barrier sealing system is configured and arranged such that it is relaxable during advancement of the carrier, said sealing system being in sealing configuration prior to an advancement of the carrier, relaxed upon an advancement of the carrier and returned to its sealing configuration at the latest after release of the powder associated with said area of the carrier.

Abstract: The disclosure describes powder inhalers and dry powder inhaler storage cassettes that include a compartment housing an elongate carrier preloaded with a plurality of doses of finely divided powder comprising a biologically active substance. The compartment is configured such that the preloaded doses are sealed within the compartment and such that the carrier may be advanced from the compartment to the chamber through an exit provided with a moisture barrier sealing system. The moisture barrier sealing system is configured and arranged such that it is relaxable during advancement of the carrier. The sealing system is in sealing configuration prior to an advancement of the carrier, is relaxed upon an advancement of the carrier and is returned to its sealing configuration at the latest after release of the powder associated with the area of the carrier.

Abstract: A dry-powder inhaler comprising a housing comprising at least one air inlet to a first air passage and a second air passage extending from the first air passage and terminating in a mouthpiece; the housing thereby providing a continuous air passage through the at least one air inlet, the first and second air passages, and the mouth piece; a rigid, fixed, powdered-medicament reservoir comprising a base, the reservoir being associated with the first air passage, and together with the first air passage forming a powder chamber; wherein air passing through the powder chamber travels substantially parallel to an upper surface of the reservoir and powdered-medicament positioned on the base in the reservoir, the upper surface of the reservoir having a surface area, and the reservoir having a volume.

Abstract: The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics.

Abstract: Systems, methods, and devices for producing hydrogen and capturing CO2 from emissions combine both H2 production and CO2 capture processes in forms of thermochemical cycles to produce useful products from captured CO2. The thermochemical cycles are copper-chlorine (Cu—Cl) and magnesium-chlorine-sodium/potassium cycles (Mg—CI—Na/K—CO2). One system comprises a Cu—Cl cycle, a CO2 capture loop, and a hydrogenation cycle. Another system comprises an Mg—CI—Na/K—CO2 cycle and a hydrogenation cycle. Devices for hydrogen production, CO2 capture, hydrogenation, and process and equipment integration include a two-stage fluidized/packed bed, hybrid two-stage spray-fluidized/packed bed reactor, a two-stage wet-mode absorber, a hybrid two-stage absorber, and a catalyst packed/fluidized bed reactor.